In contrast to the idea that tau phosphorylation is toxic, Ittner et al. (2016) recently showed that specific tau phosphorylation is neuroprotective, phenocopying tau ablation , thus highlighting the complex tau biology that underlies neurotoxicity and neuroprotection.
In contrast to the idea that tau phosphorylation is toxic, Ittner et al. (2016) recently showed that specific tau phosphorylation is neuroprotective, phenocopying tau ablation , thus highlighting the complex tau biology that underlies neurotoxicity and neuroprotection.
Tau phosphorylation is typically associated with a toxic phenotype, as neurofibrillary tangles are extensively hyperphosphorylated in post-mortem human Alzheimer's disease (AD) brain tissue and tangles are associated with neuronal death (Gó mez-Isla et al., 1997) . It has long been debated whether hyperphosphorylation of tau leads to a toxic gain of function or a loss of function. In their 2016 Science paper, Ittner et al. (2016) show a unique mechanism through which the phosphorylation of a specific residue of tau-Threonine 205-is important for protection against amyloid-b-induced excitotoxicity. In this regard, phosphorylation of tau is neuroprotective. These data are reminiscent of data from multiple labs that tau knockout or knockdown is also neuroprotective against excitotoxicty and amyloid-b-induced spine loss.
An elegant series of experiments revealed the molecular events that ultimately led to the observation of pT205 tau-associated neuroprotection. Since the kinase p38 had previously been implicated in hyperexcitability in APP-overexpressing mice, seizures were induced chemically using the GABA antagonist pentylenetetrazol in p38a, p38b, p38g, or p38d knockout mice, with only a deletion in p38g, resulting in an increase in seizure severity. Interestingly, p38g was found to localize to the post-synapse, sparing the pre-synaptic terminals. To understand this unique role of p38g in the context of amyloid-b deposition and previously reported hyperexcitability (Ittner et al., 2010) , the AD mouse model APP23 was placed onto a p38g knockout background, and as predicted, excitotoxicity was exacerbated when p38g was deleted. Additionally, APP23 3 p38g À/À mice displayed shortened survival and decreased cognitive abilities. Ittner and colleagues then asked how this may relate to the previously shown protection that results when tau is deleted in the APP23 model (Ittner et al., 2010) . Even when p38g is deleted, if there is no tau, survival and cognitive deficits are completely restored in APP23 mice. When endogenous tau is deleted in non-amyloid-containing p38g knockouts, seizure severity is significantly reduced. Conversely, when tau is overexpressed, seizures are intensified in the setting of no p38g expression. Together, these experiments suggest that p38g-unlike its other p38 counterparts-is crucial in regulating amyloid-b-induced excitotoxicity and general seizure susceptibility downstream of tau expression. Ittner et al. (2016) then delve into the mechanism through which p38g may be leading to this protective effect. In p38g knockout mice, both naive and crossed to the APP23 model, there is a significant increase in interaction between tau and the protein post-synaptic density 95 (PSD-95), the kinase fyn (previously linked with tau and hyperexcitability; Ittner et al., 2010) , and NMDA receptor subunits. This increased PSD-95/tau/fyn/NMDA receptor interaction in the absence of p38g is alternatively ablated when p38g is engineered to be constitutively active, providing strong evidence that the presence of p38g allows for the dissolution of an established postsynaptic complex that may be involved in neuronal hyperexcitability.
As a kinase, p38g is capable of phosphorylating tau at a number of residues, so as a logical next step, Ittner et al.
(2016) turned toward studying the role of these different phospho-tau epitopes and how they may impact some of the main functional readouts-seizure severity and cognition. Using a combination of mass spectroscopy and western blot analyses, Ittner et al. (2016) found one major site-pT205-that was specifically phosphorylated in the presence of p38g. Further studies revealed tau T205 as the individual site through which fyn either directly interacts with tau (dephosphorylated at T205) or dissociates from tau (phosphorylated at T205), resulting in an increase in seizure severity when T205 is unable to be phosphorylated and a decrease in seizures when T205 is pseudophosphorylated. Cognition and neuronal network synchrony were restored in the AD APP23 mouse model by injecting an AAV expressing the constitutively active form of p38g, presumably via the site-specific phosphorylation of tau at T205. While the Ittner et al. (2016) paper focuses primarily on one phosphorylation residue, the protein tau has dozens of phosphorylation sites, so it is not surprising that phosphorylation of tau is used to physiologically regulate certain functions of tau. Tau is dynamically phosphorylated and dephosphorylated at certain residues-such as Ser214, Thr231, and Ser262-to trigger tau binding with microtubules along axons in healthy neurons (Wang and Mandelkow, 2016) and, similar to the Ittner et al. (2016) paper, phosphorylation of tau at sites Ser212/Thr214, Ser202/Thr205, and Thr231 reduced the direct interaction of tau with the PSD-95/Fyn-kinase complex (Mondragó n- Rodríguez et al., 2012) . In both of these examples, it is clear that phosphorylation of tau at specific sites occur under normal conditions. These results also bring to mind substantial evidence that genetic ablation of tau, or knockdown of the endogenous tau gene therapeutically, also leads to protection from Ab-induced spine loss and from excitotoxicity (DeVos et al., 2013; Ittner et al., 2010; Roberson et al., 2007) . Moreover, both human and mouse tau reduction protects against neurodegeneration in the setting of mutant human tau overexpression Wegmann et al., 2015) . In the context of human tau aggregation, lowering total expression of tau was not only capable of preventing and reversing tau pathology, but survival was significantly extended and neuronal loss abrogated . These results open the door toward multiple complementary therapeutic approaches: targeting tau with antibodies (Nobuhara et al., 2017; Yanamandra et al., 2013) , lowering total tau expression using antisense oligonucleotides or gene therapy with zinc finger or CRISPR-cas9, or, theoretically, by applying knowledge of specific posttranslational modifications that mimic the protective tau null phenotype.
It is still unknown whether lowering total levels of the tau protein will be safe in humans. Some groups have reported detrimental phenotypes in the genetic tau knockout mice (Lei et al., 2012) , providing some level of caution for the total lowering of the protein. As an alternative to targeting total expression, one could begin to imagine a circumstance in which certain post-translational modifications of tau, such as phosphorylation of T205, creates a reversible loss-of-function phenotype without altering other protein functions. Such a model suggests a complex differential interactome of tau based on its phosphorylation state and cellular context, as well as the presence of toxic environments, such as Abeta, tangles, or seizures. The Ittner results and the recent studies of tau ablation provide an intriguing window into the complex biology of soluble tau and its relationship with neurotoxicity and neuroprotection.
